556
Participants
Start Date
January 24, 2020
Primary Completion Date
January 12, 2022
Study Completion Date
January 31, 2026
Orsiro DES
Orsiro is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform), and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.
Columbia University Medical Center, New York
Weill Cornell Medical College, New York
Maimonides Medical Center, Brooklyn
Penn State Health Holy Spirit Medical Center, Camp Hill
MedStar Washington Hospital Center, Washington D.C.
MedStar Union Memorial Hospital, Baltimore
University of Virginia Health System, Charlottesville
Charleston Area Medical Center Memorial Hospital, Charleston
AnMed Health, Anderson
Piedmont Heart Institute, Atlanta
AdventHealth Tampa, Tampa
Cardiology Associates of Mobile, Fairhope
Vanderbilt University Medical Center, Nashville
University of Kentucky, Lexington
Mercy Health - St Vincent Medical Center, Toledo
Ascension St. Vincent Medical Group, Indianapolis
University of Michigan Medical Center, Ann Arbor
Minneapolis Heart Institute, Minneapolis
Advocate Lutheran General Hospital, Park Ridge
University of Illinois, Chicago
University of Chicago Medical Center, Chicago
Ascension Via Christi Hospitals, Wichita
Baylor Heart and Vascular Hospital, Dallas
UT Health Science Center, Houston
Seton Medical Center Austin, Austin
Austin Heart, Austin
St. Joseph Hospital Orange, Orange
John Muir Medical Center, Concord
Northern Light Cardiology, Bangor
Massachusetts General Hospital, Boston
Brigham and Women's Hospital, Boston
Baystate Medical Center, Springfield
Saint Michael's Medical Center, Newark
Lead Sponsor
Biotronik, Inc.
INDUSTRY